Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years Old): Results from a pooled analysis of 2 studies

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 13, Issue 1, 2011, Pages

  Robb, Adelaide S ^a   Andersson, Candace ^b   Bellocchio, Elizabeth E ^b   Manos, George ^b   Rojas Fernandez, Carlos ^c   Mathew, Suja ^c   Marcus, Ronald ^b   Owen, Randall ^b   Mankoski, Raymond ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ARIPIPRAZOLE; PLACEBO;

ADOLESCENT; AGGRESSION; AGITATION; AKATHISIA; ARTICLE; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; BLUNTED AFFECT; CHILD; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; CONVULSION; COUGHING; DECREASED APPETITE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; EYE TOXICITY; FATIGUE; FEMALE; GAIT DISORDER; HUMAN; HYPERACTIVITY; HYPERKINESIA; HYPERSALIVATION; HYPERTENSION; IMPULSIVENESS; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LACERATION; LETHARGY; MAJOR CLINICAL STUDY; MALE; MANIA; MENTAL DISEASE; METABOLIC PARAMETERS; MULTICENTER STUDY; MUSCULOSKELETAL STIFFNESS; PARALLEL DESIGN; PATIENT COMPLIANCE; PRESYNCOPE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SOCIAL AVOIDANCE BEHAVIOR; SOMNOLENCE; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINE INCONTINENCE; VOMITING; WEIGHT CHANGE; WEIGHT GAIN;

EID: 79952789513     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.10m01008gry     Document Type: Article

References (17)

1. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. Volkmar F, Cook E Jr, Pomeroy J, et al; American Academy of Child and Adolescent Psychiatry. Summary of the practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 1999;38(12):1611-1616. PubMeddoi:10.1097/00004583-199912000-00028
3. McDougle CJ, Stigler KA, Erickson CA, et al. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry. 2008;69(suppl 4):15-20. PubMed
4. Malone RP, Waheed A. The role of antipsychotics in the management of behavioural symptoms in children and adolescents with autism. Drugs. 2009;69(5):535-548. PubMeddoi:10.2165/00003495-200969050-00003
5. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 2008;69(suppl 4):26-36. PubMed
6. Owen R, Sikich L, Marcus R, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533-1540. PubMeddoi:10.1542/peds.2008-3782
7. Marcus R, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110-1119. PubMed doi:10.1097/CHI.0b013e3181b76658
8. Aman MG, Singh NN. Aberrant Behavior Checklist: Manual. East Aurora, NY: Slosson Educational Publications; 1986.
9. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24(5):659-685. PubMed doi:10.1007/BF02172145
10. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976: 218-222.
11. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45(S212):11-19. PubMed doi:10.1111/j.1600-0447.1970.tb02066.x
12. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676. PubMed doi:10.1192/bjp.154.5.672
13. Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976: 534-537.
14. Vitiello B, Correll C, van Zwieten-Boot B, et al. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19(9):629-635. PubMed doi:10.1016/j.euroneuro.2009.04.008
15. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28(3):191-208. PubMed doi:10.2165/00002018-200528030-00002
16. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45(7):771-791. PubMed
17. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773. PubMed doi:10.1001/jama.2009.1549